Publications by authors named "Tim Leach"
Article Synopsis
- The study explores the impact of COVID-19 on patients with glomerulonephritis (GN) by analyzing data from 125 GN patients and 83 non-GN controls, focusing on kidney health outcomes over an average follow-up period of 6.4 months.
- Findings indicate that there were no significant differences in mortality or acute kidney injury (AKI) between GN patients and controls, with pre-COVID-19 kidney function (eGFR) being a critical predictor of AKI risk.
- GN patients show a lower likelihood of recovering kidney function post-AKI compared to controls, particularly those with shorter GN diagnoses or higher protein levels, suggesting a need for careful monitoring of these patients after COVID-19.
Coronary heart disease is a leading cause of death among Americans for which coronary artery bypass graft (CABG) surgery is a standard surgical treatment. The success of CABG surgery is impaired by a compliance mismatch between vascular grafts and native vessels. Tissue engineered vascular grafts (TEVGs) have the potential to be compliance matched and thereby reduce the risk of graft failure.
View Article and Find Full Text PDFObjective: The α4β7 integrin monoclonal antibody vedolizumab is hypothesised to be gut selective. Effects of vedolizumab on immune responses to parenterally or enterally administered antigens were investigated.
Design: In this randomised, double-blind, placebo-controlled, phase I trial, healthy participants received a single intravenous dose of vedolizumab 750 mg (n=64) or placebo (n=63).